FY2024 EPS Estimates for Liquidia Increased by HC Wainwright

Liquidia Co. (NASDAQ:LQDA) – Equities researchers at HC Wainwright upped their FY2024 earnings per share estimates for shares of Liquidia in a research report issued on Thursday, November 14th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($1.51) per share for the year, up from their prior estimate of ($1.54). HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Liquidia’s FY2025 earnings at ($1.62) EPS and FY2028 earnings at ($0.16) EPS.

Other equities research analysts also recently issued reports about the stock. Lifesci Capital initiated coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. BTIG Research dropped their price objective on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Finally, Scotiabank began coverage on Liquidia in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.00.

Liquidia Price Performance

NASDAQ LQDA opened at $9.82 on Monday. The stock has a market capitalization of $831.14 million, a P/E ratio of -6.02 and a beta of 0.21. The firm’s 50-day moving average is $10.52 and its two-hundred day moving average is $11.47. Liquidia has a 12 month low of $6.33 and a 12 month high of $16.99.

Hedge Funds Weigh In On Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of LQDA. Swiss National Bank acquired a new stake in Liquidia in the first quarter valued at $1,325,000. Sei Investments Co. purchased a new position in shares of Liquidia in the 1st quarter valued at about $531,000. Vanguard Group Inc. raised its position in shares of Liquidia by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after acquiring an additional 43,352 shares in the last quarter. American International Group Inc. lifted its stake in Liquidia by 5.2% during the first quarter. American International Group Inc. now owns 24,806 shares of the company’s stock worth $366,000 after purchasing an additional 1,215 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Liquidia in the first quarter valued at approximately $1,755,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Activity

In related news, insider Rajeev Saggar sold 2,260 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the sale, the insider now directly owns 207,383 shares in the company, valued at approximately $2,304,025.13. This represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Caligan Partners Lp purchased 150,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was purchased at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the purchase, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. The trade was a 2.19 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 21,551 shares of company stock worth $236,021. Corporate insiders own 30.10% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).